tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Lucid Diagnostics price target raised to $7.75 from $7.50 at Ascendiant

Ascendiant raised the firm’s price target on Lucid Diagnostics (LUCD) to $7.75 from $7.50 and keeps a Buy rating on the shares following the Q1 report. The firm says expected high growth in 2025 should drive the stock “much higher.”

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1